Immunicom Presentation outlines breakthrough subtractive Therapy’s Role in “New Era” Cancer Care at LSI’s Annual Emerging MedTech Summit.
Presently, global clinical trials are evaluating Immunicom’s ImmunopheresisTM filtration-based treatment in late-stage cancer patients to catch immuno-inhibitory targets.
It is claimed by the Immunicom CEO that cancer treatment standards will evolve with better quality-of-life and efficacy outcomes by applying new non-pharmaceutical immune-oncology strategies such as subtractive Immunopheresis.
Amir Jafri, Founder and CEO of Immunicom, discussing the potential advantages of Immunicom’s subtractive treatment strategy, Immunopheresi, in contrast to the normal methods of care treatments. The top oncology product, the LW-02 column, is a molecularly engineered blood filtration device designed to safely capture immune inhibitors shed by cancer cells to block anti-tumor activity and is extremely effective for patients in the last stages of cancer.
This non-pharmaceutical subtractive immunotherapy approach is designed to maintain patients’ quality-of-life with assuring, non-toxic cancer therapy, presented information about Immunicom’s ImmunopheresisTM filtration-based treatment at the “Emerging Medtech Summit 2021”, which is a yearly forum highlighting developing medical technology hosted by Life Science Intelligence (LSI), a leading consulting group for the global healthcare system.
They say, “Immunicom is pioneering the cancer industry with new technology and conducting multiple global cancer trials using this new treatment modality. Important conferences like LSI give us the opportunity to show prominent healthcare leaders the potential of Immunopheresis”
Immunicom, Inc. creates innovative immunotherapies composed to treat a vast diversity of diseases using its breakthrough ImmunopheresisTM technology platform to enhance patient access and affordability. The privately-held medical technology company develops innovative, non-pharmaceutical approaches for treating cancer, autoimmune disorders, and inflammatory and renal diseases.
Immunicom’s innovative blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types, including those that have not responded to other treatment strategies, with possibly fewer side effects. Immunicom’s lead product, the LW-02 column, has received U.S. FDA Breakthrough Device designation for stage IV metastatic cancer and European regulatory clearance (CE Mark certification) for use in adults with advanced, refractory, triple-negative breast cancer (TNBC).
Immunopheresis is now being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Philadelphia, PA, Houston, TX, and Krakow, Poland.
If this works effectively and becomes available throughout the globe, people will not have to live in dread of cancer and it is anticipated this breakthrough therapy will shower hope for millions of people.
Almost 10 million people die from cancer yearly, one of the world’s largest health problems. Every sixth death in the world is due to cancer.